Research Article

Comparison of Clinical Features and Treatment Outcome in Benign and Malignant Lacrimal Sac Tumors

Che-Yuan Kuo,1 Chieh-Chih Tsai,1,2 Shu-Ching Kao,1 Wen-Ming Hsu,3 and Catherine Jui-Ling Liu1,2

1Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
2Department of Ophthalmology, School of Medicine, National Yang-Ming University, Taipei, Taiwan
3Taipei Medical University-Shuang-Ho Hospital, Ministry of Health and Welfare, New Taipei City, Taiwan

Correspondence should be addressed to Chieh-Chih Tsai; cctsai1234@yahoo.com

Received 6 May 2019; Accepted 3 October 2019; Published 31 January 2020

Academic Editor: Kwang Gi Kim

Copyright © 2020 Che-Yuan Kuo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To compare the clinical characteristics and treatment outcome between benign and malignant lacrimal sac tumors. Methods. We retrospectively reviewed the medical records of all patients with pathologically confirmed lacrimal sac lesions from 1995 to 2018 in a tertiary medical center. Results. Among 65 eligible cases, 46 (70.8%) were benign lacrimal sac tumors and 19 (29.2%) were malignant lacrimal sac tumors. Secondary malignancy from nasal or paranasal cancer accounted for 47% of malignant lacrimal sac tumors. The patient’s mean age at the time of diagnosis was 60 years in the benign group and 48 years in the malignant group (p < 0.03). The most common presenting symptoms were a palpable lump/mass and epiphora in both groups. Palpable mass extending above the medial canthal tendon was noted in 9% of the benign group and in 74% of the malignant group, respectively (p < 0.001). Bloody tears were noted in 5% of the benign group and in 20% of the malignant group (p = 0.21). In the malignant group, 10 (52.6%) were primary tumors and 9 (47.4%) were secondary tumors. The primary sites of the metastatic tumor to the lacrimal sac area were mostly from neighboring paranasal sinuses and nasal cavity. The recurrence rate was higher in patients with malignant tumors, as compared to the benign tumors (42% and 6%, respectively, p = 0.001). The metastatic rate was 47% and the mortality rate was 53% in malignant lacrimal sac tumors. Conclusion. Although benign and malignant lacrimal sac tumors may present similar initial symptoms, timely diagnosis and intervention for malignant lacrimal sac lesions are important because they tend to be infiltrating tumors with a poor outcome.

1. Introduction

Lacrimal sac tumors are relatively rare compared to other ocular adnexal tumors. Diagnosis of these tumors is often delayed because they are usually confused with inflammatory dacryocystitis [1–6]. Moreover, because of its location between paranasal sinus and the orbit, lacrimal sac tumor is less noticeable during its initial stage than eyelid tumor or conjunctival tumor. Most published studies mainly focused on malignant lacrimal sac tumors. In the current study, we compare the clinical characteristics and treatment outcome between benign and malignant lacrimal sac tumors.

2. Method

We retrospectively reviewed the medical records of all patients with pathologically confirmed lacrimal sac lesions who were treated at Taipei Veterans General Hospital between 1995 and 2018. Collected data included age, gender, initial presenting symptoms, signs, computed tomography (CT) imaging, treatment, and outcome. The clinical features and treatment outcome difference between benign and malignant lacrimal sac tumors were compared. Data were calculated using Microsoft Office Excel 2016. Significant differences between the two groups were studied using 2-tailed Student’s t-test and Fisher’s exact test. A value of
The age at the time of diagnosis was relatively younger in patients with primary malignant lacrimal tumors as compared to that in secondary malignant lacrimal sac tumors (43.5 vs. 51.6 years, \( p = 0.07 \)). Local recurrence rate, metastatic rate, and mortality rate were high and similar in both groups.

4. Discussion

Our study revealed that the initial presenting symptoms such as epiphora and a lump or swelling in the lacrimal sac area are often similar in both benign and malignant lacrimal sac lesions. However, tumor mass extending above the medial canthal tendon remained an important red flag sign suggestive of malignant lacrimal sac tumors. Besides, imaging features such as bone erosion or infiltrative lesions would also indicate the possibility of malignancy. In particular, secondary malignancy accounted for 47% of malignant lacrimal sac tumors and may present with nasal symptoms. They often infiltrated from paranasal sinus or nasal cavity to lacrimal sac and showed a poor outcome.

Because malignant lacrimal sac tumors are rare, the number of subjects recruited in the current study is limited. In the present study, we found that in patients with primary malignant lacrimal sac tumors, the mean age at the time of diagnosis was 43.5 years, which was younger than that of secondary malignant lacrimal sac tumors (51.6 years) and benign lacrimal sac tumors (60 years). Previous studies also reported that the malignant lacrimal sac tumors often occurred in the fifth decade [7–10]. No significant gender difference between benign and malignant lacrimal tumors was found in the current study. Bi et al. reported in a retrospective study of 96 cases that primary lacrimal sac tumors occurred more often in men in than women (M:F = 1.8:1.0), but Parmar and Rose revealed the opposite result (M:F = 1.0:2.75) [9, 11]. In subgroup analysis for malignant lacrimal sac tumors, we found female predominance in the primary malignant group and male predominance in the secondary malignant group. Since most of the secondary lacrimal sac tumors originated from adjacent structures, such as paranasal sinuses and nasal cavity, we hypothesized that the reason for this gender predilection may attribute to that men are traditionally more likely to develop nasopharyngeal cancer or nasal tumors than women [12].

In a review article reported by Krishna and Coupland, more than 55% of the lacrimal sac tumors were malignant [8]. However, the malignant tumors accounted for only about 30% in our study, which may be resulted from a higher percentage of benign subjects enrolled. Similar initial symptoms mimicking benign lesions and less noticeable tumor location could cause delayed diagnosis of malignant lacrimal sac tumors [13]. Moreover, because of its location between paranasal sinus and the orbit, management of lacrimal sac tumors is quite challenging and often requires adjuvant therapy [4, 14–18]. Regarding the prognosis, Elsawy et al. proposed that the eye can be spared and visual function can be preserved with multidisciplinary therapy [14]. However, despite the aggressive treatments, 53% of the malignant cases in the present study still died of the disease. In a case series published by Parmar and Rose, 20% (3/15) of

\( p < 0.05 \) was considered statistically significant. This study was approved by the institutional review board of Taipei Veterans General Hospital and was conducted in accordance with the Declaration of Helsinki.
Based on current findings and previous studies, we will suggest that lacrimal sac malignancy should always be beard in mind in patients with epiphora and swelling/mass over medial canthal region. Comprehensive history taking including sinonasal symptoms, physical examinations, and imaging studies can be helpful in early diagnosis and the management of malignant lacrimal sac tumors to reduce the morbidity and mortality caused by malignant lacrimal sac tumors.

**Data Availability**

The clinical data used to support the findings of this study are included within the article.

**Conflicts of Interest**

None of the authors have any conflicts of interest in relation to the work described.

**Acknowledgments**

This study was partially supported by grants (MOST 108-2314-B-075-056) from the Ministry of Science and Technology.

### Table 1: Initial presenting symptoms among patients with lacrimal sac lesions.

| Symptom                  | Benign | Primary | Malignant | Secondary | p value |
|--------------------------|--------|---------|-----------|-----------|---------|
| Lump/mass                | 9/19*  | 6/10 (60%) | 3/6* (50%) |           | 0.8     |
| Epiphora                 | 6/19*  | 5/10 (50%) | 2/6* (33%) |           | 0.61    |
| Discharge                | 3/19*  | 1/10 (10%) |           |           | 0.54    |
| Pain                     | 2/19*  | 4/10 (40%) |           |           | 0.06    |
| Bloody tears             | 1/19*  | 2/10 (20%) |           |           | 0.21    |
| Proptosis                |        | 2/10 (20%) |           |           |         |
| EOM limitation           |        | 1/10 (10%) |           |           |         |
| Nasal obstruction        |        | 1/6 (17%)  |           | 1/6* (17%)|         |
| Epistaxis                |        | 1/6 (17%)  |           | 1/6* (17%)|         |
| Tinnitus                 |        |           |           | 1/6* (17%)|         |
| Otalgia                  |        |           |           | 1/6* (17%)|         |

Values are presented as n (%). *Symptom data were available on 19 patients with benign lesions, 10 patients with primary malignant lesions, and 6 patients with secondary malignant lesions.

### Table 2: Comparison of demographic features and treatment outcomes between benign and malignant lacrimal sac tumors.

| Feature                                      | Benign (n = 46) | Malignant (n = 19) | p value |
|----------------------------------------------|-----------------|--------------------|---------|
| Gender                                       |                 |                    |         |
| Male                                         | 19              | 11                 | 0.22    |
| Female                                       | 27              | 8                  |         |
| Mean onset age (years)                       | 60.2 ± 15.2     | 48 ± 9.3           | 0.03*   |
| Mass extending above the medial canthal tendon | 4/46 (9%)     | 14/19 (74%)        | <0.001* |
| CT imaging                                  |                 |                    |         |
| Bone erosion                                 | 1/9 (11%)       | 8/16 (50%)         | <0.05*  |
| Infiltrative lesion                          | 0/9 (0%)        | 10/16 (63%)        | <0.05*  |
| Treatment                                    |                 |                    |         |
| Surgical resection                          | 38              | 19                 |         |
| Adjuvant RT                                  | 8               |                    |         |
| Adjuvant CCRT                                | 9               |                    |         |
| Local recurrence rate                        | 3/46 (6%)       | 8/19 (42%)         | 0.001*  |
| Metastatic rate                              | 0               | 9/19 (47%)         |         |
| Mortality rate                               | 0               | 10/19 (53%)        |         |
| Mean follow-up time (months)                 | 48.9 (0.25–128) | 76.2 (3–168)       |         |

Values are presented as n (%), mean ± SD or mean (range). CT, computed tomography; RT, radiotherapy; CCRT, concurrent chemoradiotherapy. *p < 0.05. **CT imaging data were available on 9 patients with benign lesions and 16 patients with malignant lesions.

### Table 3: Comparison of demographic features and treatment outcomes between primary and secondary malignant lacrimal sac tumors.

| Feature                                      | Primary (n = 10) | Secondary (n = 9) | p value |
|----------------------------------------------|-----------------|-------------------|---------|
| Gender                                       |                 |                   |         |
| Male                                         | 3               | 8                 | 0.02*   |
| Female                                       | 7               | 1                 |         |
| Mean age (years)                             | 43.5 ± 3.1      | 51.6 ± 11.3       | 0.21    |
| Local recurrence rate                        | 2/10 (20%)      | 6/9 (67%)         | 0.07    |
| Metastatic rate                              | 5/10 (50%)      | 4/9 (44%)         | 1       |
| Mortality rate                               | 5/10 (50%)      | 5/9 (56%)         | 1       |

Values are presented as n (%) or mean ± SD. *p < 0.05.

patients developed metastasis, and 20% (3/15) of patients died during the follow-up interval [11].

Based on current findings and previous studies, we will suggest that lacrimal sac malignancy should always be beard in mind in patients with epiphora and swelling/mass over medial canthal region.
Technology, Taiwan, and a grant (V108-C-112) from Taipei Veterans General Hospital, Taiwan.

References

[1] E. J. Wladis, T. Frempong, and R. Gausas, "Nasolacrimal metastasis from hepatocellular carcinoma masquerading as dacryocystitis," Ophthalmic Plastic & Reconstructive Surgery, vol. 23, no. 4, pp. 333–335, 2007.

[2] F. Kajita, T. Oshitari, J. Yotsukura et al., "Case of primary diffuse large B-cell lymphoma of lacrimal sac in a Japanese patient," Clinical Ophthalmology, vol. 2010, no. 4, pp. 1351–1354, 2010.

[3] J. Ding, H. Sun, Y. Xin, and D. Li, "Metastatic hepatocellular carcinoma mimicking acute dacryocystitis," Canadian Journal of Ophthalmology, vol. 53, no. 4, pp. e132–e134, 2018.

[4] L. N. Lee, A. R. Scott, A. W. Chan, and R. A. Frankenthaler, "Management of transitional cell carcinoma of the lacrimal sac: a multidisciplinary approach to orbit sparing treatment," The Laryngoscope, vol. 120, no. 5, p. S161, 2010.

[5] L. M. Heindl, B. Schick, E. Kämpgen, F. E. Kruse, and L. M. Holbach, "Malignes Melanom des Tränensacks," Der Ophthalmologe, vol. 105, no. 12, pp. 1146–1149, 2008.

[6] G. Avgitidou, H. Göbel, C. Cursiefen, and L. M. Heindl, "Epiphora bei druckindolenter schwellung des auge-ninenwinkels," Der Ophthalmologe, vol. 111, no. 8, pp. 778–780, 2014.

[7] X. Song, J. Wang, S. Wang, W. Wang, S. Wang, and W. Zhu, "Clinical analysis of 90 cases of malignant lacrimal sac tumor," Graefes Archive for Clinical and Experimental Ophthalmology, vol. 256, no. 7, pp. 1333–1338, 2018.

[8] Y. Krishna and S. E. Coupland, "Lacrimal sac tumors—A review," Asia-Pacific Journal of Ophthalmology, vol. 6, no. 2, pp. 173–178, 2017.

[9] Y. W. Bi, R. J. Chen, and X. P. Li, "Clinical and pathological analysis of primary lacrimal sac tumors," [Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology, vol. 43, no. 6, pp. 499–504, 2007.

[10] M. A. Stefanyszyn, A. A. Hidayat, J. J. Pe’er, and J. C. Flanagan, "Lacrimal sac tumors," Ophthalmic Plastic & Reconstructive Surgery, vol. 10, no. 3, pp. 169–184, 1994.

[11] D. N. Parmar and G. E. Rose, "Management of lacrimal sac tumours," Eye, vol. 17, no. 5, pp. 599–606, 2003.

[12] S. H. Xie, I. T. Yu, L. A. Tse, O. W. Mang, and L. Yue, "Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983–2008: suggestion of a potential protective role of oestrogen," European Journal of Cancer, vol. 49, no. 1, pp. 150–155, 2013.

[13] L. M. Heindl, E. Treutlein, A. G. M. Jünemann, F. E. Kruse, and L. M. Holbach, "Selektive tränensackbiopsie bei externer dakryozyosthorinostomie," Der Ophthalmologe, vol. 107, no. 12, pp. 1139–1144, 2010.

[14] T. El-Sawy, S. J. Frank, E. Hanna et al., "Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas," Ophthalmic Plastic and Reconstructive Surgery, vol. 29, no. 6, pp. 454–457, 2013.

[15] X. Song, S. Wang, J. Wang et al., "Clinical management and outcomes of lacrimal sac squamous cell carcinoma," Head & Neck, vol. 41, no. 4, pp. 974–981, 2019.

[16] T. Goto, N. Bandoh, T. Nagato et al., "Primary small cell carcinoma of lacrimal sac: case report and literature review," The Journal of Laryngology & Otology, vol. 124, no. 11, pp. 1223–1226, 2010.